Summary

Background & aims: Long-term safety data for anti TNF therapies are needed. Methods: We retrospectively evaluated data patients for safety related outcomes from Uppsala Monitoring Centre (UMC). The data were collected during six years for infliximab and etanercept; and three years for adalimumab. Results: The etanercept had a double of events compared with infliximab and it a double compared with adalimumab, although in three years of follow up. The profile of event adverse differed among these drugs. Conclusions: Data more five years are necessary for all anti-TNF therapies and these could help explain the differences in security and clinic relevance of them.